Dave What if the future of aging wasn't about slowing down but switching on? At Dave Asprey's Biohacking Conference this May 2830 in Austin, BioLongevity Labs is bringing something game changing Bioengineered human arterial equivalent and its applications from vascular graft to in vitro disease modeling ScienceDirect BPC 157 in Australia: Benefits, side effects, risks and legality First and foremost, my MS isn't as bad as a lot of yall. I mostly have weak knees, balance issues, spasticity, and clonus. That said I recently started on BCP 157 Peptides. It's